RT TrendSpider (@TrendSpider)For the IPO base breakout enjoyers. $RIVN 🤝 $HOOD https://t.co/c1w3khGHVW ...

Core Viewpoint - Medtronic's diabetes unit, MiniMed Group, has filed for an initial public offering (IPO) as part of its separation from Medtronic, with the aim to repay intercompany debt and fund corporate purposes [1][2]. Financial Performance - MiniMed reported a net loss of $21 million on net sales of $1.48 billion for the six months ending October 24, compared to a net loss of $23 million on net sales of $1.3 billion in the same period the previous year [1]. IPO Details - The IPO will be underwritten by Goldman Sachs, BofA Securities, Citigroup, and Morgan Stanley, and MiniMed plans to list on Nasdaq under the symbol "MMED" [4]. - Medtronic will retain at least 80.1% of the voting stock in MiniMed post-IPO, with plans to distribute its stake to shareholders through a spin-off or split-off [3]. Market Context - The IPO market is showing signs of recovery after a slow start to the year, with increased activity expected in 2026, particularly in January and the first quarter [4][5].

Group 1 - The A-share IPO market in 2025 is expected to see 114 companies listed, raising a total of 129.6 billion yuan, representing a 94% year-on-year increase [1][2] - The average first-day closing price increase for new stocks is 257%, marking the best performance in three years, with 32 stocks seeing first-day gains exceeding 300% [1][3] - The Hong Kong IPO market is projected to regain the top position globally, with 114 new stocks expected to raise approximately 286.3 billion HKD, a significant increase from 70 stocks and 87.5 billion HKD in 2024 [4][5] Group 2 - The increase in A-share IPOs is attributed to supportive policies such as the new "National Nine Articles" and the "1+N" series of capital market policies, leading to a notable rise in both quantity and quality of listings [2] - The electronics, power equipment, automotive, basic chemicals, and machinery sectors are the main contributors to IPOs, accounting for about 65% of the total new stocks [2] - The Hong Kong market has seen a surge in large-scale IPOs, with eight new stocks each raising over 10 billion HKD, contributing to half of the total financing amount [4][6]

Group 1: Stock Market Performance - The US stock market saw a collective rise on December 19, with the Dow Jones Industrial Average up 0.38% to 48,134.89 points, the S&P 500 up 0.88% to 6,834.5 points, and the Nasdaq up 1.31% to 23,307.62 points [1] - European indices also experienced slight gains, with the German DAX up 0.39% to 24,293.56 points, the French CAC40 up 0.01% to 8,151.38 points, and the UK FTSE 100 up 0.61% to 9,897.42 points [1] - The Nasdaq Golden Dragon China Index rose 0.86%, with notable individual stock performances including Pony.ai up nearly 12% and Hesai Technology up over 7% [1] Group 2: AI Sector Developments - Oracle's stock rose over 6% following the announcement of a joint venture with TikTok, which includes Oracle, Silver Lake, and MGX [3] - Nvidia's stock increased by approximately 4%, amid reports of the Trump administration reviewing the company's export of advanced AI chips to China [3] - CoreWeave's stock surged over 22%, while other AI-related companies like AMD and Broadcom also saw gains [4] Group 3: Other Notable Company Movements - Nike's stock fell over 10% after the company projected a decline in sales [5] - Morgan Stanley is expected to lead the underwriting for SpaceX's IPO, leveraging its long-standing relationship with CEO Elon Musk [6][7][8] Group 4: Commodity Market Insights - Gold futures rose by 0.1% to $4,368.7 per ounce, with a weekly increase of 0.9%, while silver futures increased by 3.34% to $67.395 per ounce, marking an 8.55% weekly rise [10] - Oil prices also saw a rebound, with West Texas Intermediate crude up 0.96% to $56.54 per barrel and Brent crude up 1.01% to $60.1 per barrel [10]

Core Viewpoint - EchoStar's stock has recently experienced volatility but saw a positive trading session, driven by an analyst's significant price target increase [1] Group 1: Analyst Insights - Deutsche Bank analyst Bryan Kraft raised EchoStar's fair value assessment from $97 to $131 per share, indicating strong confidence in the company's future [2] - The analyst highlighted the sale of wireless spectrum to SpaceX as a key catalyst for the stock's recent price increase, along with the anticipated IPO of SpaceX, which has provided EchoStar with substantial equity [4] - Kraft also noted potential legal settlements with business partners as additional positive factors that could support EchoStar's stock price [5] Group 2: Market Data - EchoStar's current stock price is $103.91, with a market capitalization of $30 billion [6] - The stock has shown a daily trading range between $103.38 and $111.39, and a 52-week range from $14.90 to $111.39 [6] - The trading volume for EchoStar was reported at 8.4 million, compared to an average volume of 4.3 million [7]

Final trade time. Mike Poe. >> Yeah.Top line, bottom line, and free cash flow. All growing faster than the market overall, and yet it trades at a market multiple. I like Amazon.>> Tim, >> good to have Ununice here. Inspired me on my Baba trade. Alibaba.>> Courtney, we're talking about um IPOs, maybe potential M&A activity. I think Goldman Sachs is worth a look here. Steve >> GM is an incredible chart and I think it still can go higher.>> Thank you for watching Fast Money. Have a fantastic weekend. The Mad M ...

The obvious reason for SpaceX, OpenAI and Anthropic to pursue IPOs is access to more capital. But will this trump more scrutiny? https://t.co/WIZ531G6Hy ...

Core Insights - Donovan Jones is an IPO research specialist with 15 years of experience in identifying high-quality IPO opportunities [1] - He leads the investing group IPO Edge, which provides actionable information on growth stocks through various resources including IPO filings, previews, and a comprehensive IPO calendar [1] Group 1 - IPO Edge offers a database of U.S. IPOs and a guide to IPO investing, covering the entire IPO lifecycle from filing to listing and lockup expiration dates [1]

Core Insights - Donovan Jones is an IPO research specialist with 15 years of experience in identifying high-quality IPO opportunities [1] - He leads the investing group IPO Edge, which provides actionable information on growth stocks through various resources including IPO filings, previews, calendars, and a comprehensive guide to IPO investing [1] Group 1 - IPO Edge offers a database of U.S. IPOs and tracks upcoming IPOs, facilitating investors in navigating the IPO lifecycle from filing to listing [1] - The group emphasizes the importance of understanding the quiet period and lockup expiration dates in the IPO process [1]

Group 1: IPO Performance - 2025 has been a strong year for IPOs in the United States, with notable debuts from companies like Coreweave, Figma, and Circle [1] - A model portfolio of all H1 2025 US IPOs returned 75.9% through June, significantly outperforming the S&P 500's 4.9% return, driven by large deals in AI and fintech [1] Group 2: Medline Overview - Medline, founded in 1966, is a major healthcare and medical-surgical products manufacturer and distributor, operating in two segments: proprietary medical products and supply chain solutions [3] - Medline is the largest provider of medical-surgical and supply chain solutions globally, with a catalog of over 335,000 products and 69 distribution centers [6] Group 3: Medline IPO Details - Medline upsized its IPO, selling 216 million shares at $29 each, raising $6.26 billion, compared to the initial plan of 179 million shares at a price range of $26 to $30 per share [4] - The shares debuted with a 41% rally from their issue price, and the proceeds are intended for debt reduction and general corporate purposes [4] Group 4: Financial Performance - Medline's revenues have grown at a CAGR of 18% since its inception, with sales increasing from $21.45 billion in 2022 to $23.23 billion in 2023, and $25.51 billion in 2024 [7] - For the first six months of 2025, Medline reported net sales of $13.53 billion [7]